Abstract
PURPOSE: This review was undertaken to examine the evidence of the effectiveness of adjuvant chemotherapy in colorectal cancer. METHODS: Published studies were reviewed and analyzed. RESULTS: For over three decades, a large series of adjuvant systemic trials have been conducted in carcinoma of the colon and rectum in an attempt to reduce recurrence and ultimately improve survival. However, only in the last few years have significant gains been made. In colon cancer with regional nodal metastasis, combined treatment with 5-fluorouracil and levamisole has resulted in significant reduction of tumor recurrence and improved survival. In rectal cancer, combined modality treatment with radiotherapy and chemotherapy is considered the standard for care by many investigators, although numerous questions remain unanswered. CONCLUSIONS: The existing evidence suggests that adjuvant therapy may be of value in selected patients with colorectal cancer. Several currently active trials are pursuing very hopeful leads, and clinicians are encouraged to enter their patients on available trials.
Similar content being viewed by others
References
Hardcastle JD, Thomas WM, Chamberlain J,et al. Randomised controlled trial of faecal occult blood screening for colorectal cancer: results for the first 107,349 subjects. Lancet 1989;1:1160–4.
Mrazek R, Economou S, McDonald GO, Slaughter DP, Cole TO. Prophylactic and adjuvant use of nitrogen mustard in the surgical treatment of cancer. Ann Surg 1959;150:745–55.
Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 1988;259:3571–8.
Wolmark N, Fisher B, Rockette H,et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988;80:30–6.
Laurie JA, Moertel CG, Fleming TR,et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989;7:1447–56.
Moertel CG, Fleming TR, Macdonald JS,et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–8.
Moertel C, Fleming T, MacDonald J, Haller D, Laurie J. The intergroup study of fluorouracil (5-FU) plus levamisole (Lev) and levamisole alone as adjuvant therapy for stage C colon cancer. Proc Am Soc Clin Oncol 1992;11:161.
Mixed European reactions to American colorectal data. Ann Oncol 1990;1:239.
Buroker TR, Moertel CG, Fleming TR,et al. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil in colorectal carcinoma. J Clin Oncol 1985;3:1624–31.
Moertel CG. Surgical adjuvant treatment of colorectal cancer. Forum 1992;2:426–37.
O'Connell M, Mailliard J, Macdonald J, Haller D, Mayer R, Wieand H. An intergroup trial of intensive course 5FU and low dose leucovorin as surgical adjuvant therapy for high risk colon cancer. Proc Am Soc Clin Oncol 1993;12:190.
Wolmark N, Rockette H, Fisher B,et al. Leucovorinmodulated 5-FU (LV-FU) as adjuvant therapy for primary colon cancer: NSABP C-03. Proc Am Soc Clin Oncol 1993;12:197.
Zaniboni A, Erlichman C, Scitz JF,et al. FUFA increases disease-free survival (DFS) in resected B2C colon cancer (CC): results of a prospective pooled analysis of 3 randomized trials (RCTs). Proc Am Soc Clin Oncol 1993;12:191.
Taylor I, Brooman P, Rowling JT. Adjuvant liver perfusion in colorectal cancer: initial results of a clinical trial. BMJ 1977;2:1320–2.
Taylor I, Manchin D, Mullee M, Trotter G, Cooke T, West C. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985;72:359–63.
Ryan J, Weiden P, Crowley J, Bloch K. Adjuvant portal vein infusion for colorectal cancer: a 3-arm randomized trial. Proc Am Soc Clin Oncol 1988;7:95.
Gray BN, deZwart J, Fisher R. The Australia and New Zealand trial of adjuvant chemotherapy in colon cancer. In: Salmon SE, ed. Adjuvant therapy of cancer V. Philadelphia: Grune & Stratton, 1987:537–46.
Beart RW Jr, Moertel CG, Wieand HS,et al. Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. Arch Surg 1990;125:897–901.
Wolmark N, Rockette H, Wickerham DL,et al. Adjuvant therapy of Duke's A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990;8:1466–75.
Laffer U, Metzger U, Pampallona S, Castiglione M. Adjuvant intraportal chemotherapy for colorectal cancer. 8-year results of the randomized Swiss trial (SAKK 40/81). Proc Am Soc Clin Oncol 1993;12:220.
Wereldsma JC, Bruggink ED, Meijer WS, Roukema JA, van Putten WL. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of prospective randomized clinical trial (colorectal adenocarcinoma trial I). Cancer 1990;65:425–32.
Fielding LP, Hittinger R, Grace RH, Fry JS. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992;340:502–6.
Gérard A, Buyse M, Nordlinger B,et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer: final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). Ann Surg 1988;208:606–14.
Higgins GA, Humphrey EW, Dwight RW, Oswit B, Lee LE Jr, Keehn J. Preoperative radiation and surgery for cancer of the rectum: Veterans Administration Surgical Oncology Group Trial II. Cancer 1986;58:352–9.
Gastrointestinal Tumor Study Group. Prolongation of the disease-free survival in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465–72.
Bentzen SM, Baslev I, Pedersen M,et al. A regression analysis of prognostic factors after resection of Duke's B and C carcinoma of the rectum and rectosigmoid: does post-operative radiotherapy change the prognosis? Br J Cancer 1988;58:195–201.
Fisher B, Wolmark N, Rockette H,et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP Protocol R-01. J Natl Cancer Inst 1988;80:21–9.
Douglass HO Jr, Moertel CG, Mayer RJ,et al. Survival after postoperative combination treatment of rectal cancer. N Engl J Med 1986;315:1294–5.
Krook J, Moertel CG, Gunderson LL,et al. Surgical adjuvant therapy for high risk rectal carcinoma. N Engl J Med 1991;324:709–15.
O'Connell M, Wieand HS, Krook J,et al. Lack of value for methyl-CCNU as a component of rectal cancer surgical adjuvant therapy: interim analysis of Intergroup Protocol 86-47-51. Proc Am Soc Clin Oncol 1991;10:134.
Author information
Authors and Affiliations
About this article
Cite this article
Lopez, M. Adjuvant therapy of colorectal cancer. Dis Colon Rectum 37 (Suppl 2), S86–S91 (1994). https://doi.org/10.1007/BF02048438
Issue Date:
DOI: https://doi.org/10.1007/BF02048438